Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MEDI5395
i
Other names:
MEDI5395, MEDI 5395, MEDI-5395, recNDVGM-CSF, oncolytic newcastle disease virus therapeutic
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
AstraZeneca
Drug class:
G-CSF stimulant
Related drugs:
‹
Nugraf (filgrastim biosimilar) (3)
SV-BR-1-GM (2)
pegfilgrastim (1)
pegfilgrastim-jmdb (0)
GW003 (balugrastim biosimilar) (0)
lenograstim (0)
Lonquex (lipegfilgrastim biosimilar) (0)
pegfilgrastim-apgf (0)
mecapegfilgrastim (0)
RP2 (0)
eflapegrastim-xnst (0)
G-CSF and polysialic acid (0)
pegfilgrastim-cbqv (0)
pegfilgrastim-bmez (0)
recombinant G-CSF (0)
Nugraf (filgrastim biosimilar) (3)
SV-BR-1-GM (2)
pegfilgrastim (1)
pegfilgrastim-jmdb (0)
GW003 (balugrastim biosimilar) (0)
lenograstim (0)
Lonquex (lipegfilgrastim biosimilar) (0)
pegfilgrastim-apgf (0)
mecapegfilgrastim (0)
RP2 (0)
eflapegrastim-xnst (0)
G-CSF and polysialic acid (0)
pegfilgrastim-cbqv (0)
pegfilgrastim-bmez (0)
recombinant G-CSF (0)
›
Associations
News
Trials
Filter by
Latest
over1year
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors (clinicaltrials.gov)
P1, N=39, Completed, MedImmune LLC | Active, not recruiting --> Completed
over 1 year ago
Trial completion • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression
|
Imfinzi (durvalumab) • MEDI5395
over2years
A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors (clinicaltrials.gov)
P1, N=39, Active, not recruiting, MedImmune LLC | Trial completion date: May 2023 --> Dec 2022
over 2 years ago
Trial completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression
|
Imfinzi (durvalumab) • MEDI5395
almost3years
A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors (clinicaltrials.gov)
P1, N=39, Active, not recruiting, MedImmune LLC | Trial primary completion date: May 2023 --> Nov 2021
almost 3 years ago
Clinical • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression
|
Imfinzi (durvalumab) • MEDI5395
3years
A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors (clinicaltrials.gov)
P1, N=38, Active, not recruiting, MedImmune LLC | Recruiting --> Active, not recruiting | N=188 --> 38 | Trial completion date: May 2025 --> May 2023 | Trial primary completion date: May 2025 --> May 2023
3 years ago
Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression
|
Imfinzi (durvalumab) • MEDI5395
over4years
A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors (clinicaltrials.gov)
P1, N=164, Recruiting, MedImmune LLC | Active, not recruiting --> Recruiting
over 4 years ago
Clinical • Enrollment open • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression
|
Imfinzi (durvalumab) • MEDI5395
over4years
A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors (clinicaltrials.gov)
P1, N=164, Active, not recruiting, MedImmune LLC | Recruiting --> Active, not recruiting
over 4 years ago
Clinical • Enrollment closed • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression
|
Imfinzi (durvalumab) • MEDI5395
over4years
[VIRTUAL] A phase 1 study of IV MEDI5395, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors (AACR-I 2020)
Secondary objectives include assessing MEDI5395 pharmacokinetics (viremia and GM-CSF transgene expression), pharmacodynamics in the TME, immunogenicity, and initial efficacy in combination with durvalumab. The trial is actively accruing.
over 4 years ago
Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression • IFNG expression
|
Imfinzi (durvalumab) • MEDI5395
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login